Schizophrenia Clinical Trials in Miami, Florida

12 studies are recruiting for schizophrenia in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Miami, Florida

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

2. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0075, Miami, Florida

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

3. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Wellness Research Center, Miami, Florida

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

4. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Miami, Florida

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

5. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Columbus Clinical Services LLC, Miami, Florida

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

6. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

   The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

   Stage

   Not phased

   Ages

   18 and older

   Site

   Local Institution - 0019, Miami, Florida

   Locations

   20 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07101094 on ClinicalTrials.gov

7. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   Banyan Behavioal Care Program - CSU, Miami, Florida

   Locations

   55 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

8. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, Miami, Florida

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

9. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Premier Clinical Research Institute, Miami, Florida

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

10. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

    The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Segal Institute for Clinical Research, Miami, Florida

    Locations

    16 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07467993 on ClinicalTrials.gov

11. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Miami, Florida

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

12. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Miami, Florida

    Locations

    20 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov